ALX Oncology Holdings Inc. Common Stock vs. Eli Lilly & Co.
Eli Lilly & Co. (LLY) comes out ahead, leading on 4 of 6 compared factors.
Size & Scale
| ALXO | LLY | |
|---|---|---|
| Market Cap | $272.41 million | $1.05 trillion |
| Revenue (TTM) | — | $79.67 billion |
| Net Income (TTM) | $-80,890,000 | $26.71 billion |
LLY leads on 3 of 3 size & scale factors.
Valuation
| ALXO | LLY | |
|---|---|---|
| P/E Ratio | — | 41.15 |
| Price / Book | 2.00 | 31.13 |
| Price / Sales | — | 13.24 |
ALXO leads on 1 of 1 valuation factors.
Profitability
| ALXO | LLY | |
|---|---|---|
| Net Margin | — | 33.53% |
| Return on Equity | -59.40% | 78.84% |
LLY leads on 1 of 1 profitability factors.
Dividend
| ALXO | LLY | |
|---|---|---|
| Dividend Yield | — | 0.56% |
| Payout Ratio | — | 23.23 |
ALXO and LLY split the dividend factors evenly.
Risk & Sentiment
| ALXO | LLY | |
|---|---|---|
| Short Interest | 0.00% | 1.29% |
ALXO leads on 1 of 1 risk & sentiment factors.
Dig deeper: ALXO overview, ALXO financials, LLY overview, LLY financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.